Shire's Daytrana approved for adolescents with ADHD
This article was originally published in Scrip
The US FDA has approved Shire's transdermal patch product, Daytrana (methylphenidate transdermal system) the treatment of attention-deficit hyperactivity disorder (ADHD) in adolescent patients aged 13 to 17 years.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.